[ad_1]
Russia wants to market a light version of its corona Sputnik V vaccine. It is intended to serve as a temporary solution and is intended primarily for export.
By Stephan Laack, WDR
Russia has been vaccinating its population with the Sputnik V vaccine for two weeks in a broad campaign against the corona. There can be no noticeable effects yet, as two vaccines are necessary every three weeks and, according to the developer, immunity only increases after 42 days.
Now there should be an abbreviation for this process: a “Sputnik V Light Version” that Russia wants to bring to market and that works much faster. At least that is what the Gamaleja Russian Institute promises that developed it. After his big annual press conference, Russian President Putin spoke of the great potential that option would offer.
“Experts say that it is a lightweight vaccine developed by the Gamaleja Institute. It works faster with a single injection. The level of protection is lower, but the efficiency will reach 85 percent.”
Light version especially for export
So far it has been said that Russians should continue to be vaccinated with the older Sputnik V vaccine. The light version is primarily intended for export abroad in order to be used in hotspot regions and rapidly reduce the number of infections there. A temporary solution, because the effect should last three to four months. The director of the Gamaleja Institute in Ginzburg sees the Sputnik V light version as an important addition to other existing vaccines.
“No company in the Russian Federation, Western Europe, the United States, or the entire world can rapidly produce the required amount of vaccine compounds against a pandemic that has spread throughout the world. Therefore, this vaccine of which our president spoke today makes possible a trade-off between the duration of action of the Sputnik-V vaccine and the need to rapidly reduce the maximum incidence, including mortality, of this disease with a single component of this vaccine. “
Russia is one of the first countries in the world to vaccinate its population against corona on a large scale, but before the end of the third and decisive test phase of the Sputnik V vaccine. The first significant results should be available early next year. year. The World Health Organization (WHO) is very interested in this, as it is assumed that a whole range of vaccines from different manufacturers will be needed to meet global demand.
